骨髄線維症治療薬の世界市場2018-2022

◆英語タイトル:Global Myelofibrosis Therapeutics Market 2018-2022
◆商品コード:IRTNTR23859
◆発行会社(リサーチ会社):Technavio
◆発行日:2018年12月21日
◆ページ数:106
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、骨髄線維症治療薬の世界市場について調査・分析し、市場概要、市場環境、骨髄線維症治療薬市場規模、治療別(薬物療法、輸血、HSCT、アンドロゲン療法)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・骨髄線維症治療薬の世界市場概要
・骨髄線維症治療薬の世界市場環境
・骨髄線維症治療薬の世界市場動向
・骨髄線維症治療薬の世界市場規模
・骨髄線維症治療薬の世界市場:業界構造分析
・骨髄線維症治療薬の世界市場:治療別(薬物療法、輸血、HSCT、アンドロゲン療法)
・骨髄線維症治療薬の世界市場:地域別市場規模・分析
・骨髄線維症治療薬の北米市場規模・予測
・骨髄線維症治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・骨髄線維症治療薬のアジア太平洋市場規模・予測
・骨髄線維症治療薬の主要国分析
・骨髄線維症治療薬の世界市場:意思決定フレームワーク
・骨髄線維症治療薬の世界市場:成長要因、課題
・骨髄線維症治療薬の世界市場:競争環境
・骨髄線維症治療薬の世界市場:関連企業情報(ベンダー分析)
【レポートの概要】

About this market
Myelofibrosis is as Philadelphia chromosome- negative myeloproliferative neoplasm (MPN), a rare mutation. The only FDA approved drug therapy is JAKAVI/JAKAFI (Ruxolitinib). It is a potent oral JAK1/ JAK2 inhibitor used for treating the patients with myelofibrosis. HSCT therapy is also having disadvantages regarding the unavailability of matching donors. Other therapies, including the transfusion and androgen therapy, merely reduce the anemic side effects of myelofibrosis. Thus, among all treatments available at present, none can be considered as an ideal one that can completely help in eradicating the disease. Technavio’s analysts have predicted that the myelofibrosis therapeutics market will register a CAGR of more than 7% by 2022.
Market Overview
Increasing number of companies entering the myelofibrosis segment
Before the launch of JAKAVI/JAKAFI, there were very few companies investing in the R&D of myelofibrosis therapies.
Limited market size as myelofibrosis is a rare disorder
The number of available therapies including the orphan drugs for this disorder is very limited. The treatment options employed by physicians are mostly the off- label drugs that are meant for the treatment of some other condition or the blood transfusion or stem cell transplantation.
For the detailed list of factors that will drive and challenge the growth of the myelofibrosis therapeutics market during the 2018-2022, view our report.
Competitive Landscape
The global myelofibrosis therapeutics market is extremely concentrated. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: PIPELINE ANALYSIS
• Pipeline analysis
PART 06: MARKET SIZING
Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: MARKET SEGMENTATION BY TYPE OF TREATMENT
• Segmentation by type of treatment
• Comparison by type of treatment
• Drug therapy – Market size and forecast 2017-2022
• Blood transfusion – Market size and forecast 2017-2022
• HSCT – Market size and forecast 2017-2022
• Androgen Therapy – Market size and forecast 2017-2022
• Market opportunity by type of treatment
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 13: MARKET TRENDS
• HSCT is the only curative option for myelofibrosis
• High off-label prescription including hydroxyurea, Immunomodulators, and steroids
PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 15: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bristol-Myers Squibb
• CELGENE
• Incyte
• Novartis
PART 16: APPENDIX
• List of abbreviations



Exhibit 01: Global oncology therapeutics market
Exhibit 02: Global oncology therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline molecules for myelofibrosis 2017-2018
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global – Market size and forecast 2017-2022 ($ mn)
Exhibit 10: Global – Year-over-year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition – Five forces 2017
Exhibit 19: Type of treatment – Market share 2017-2022 (%)
Exhibit 20: Comparison by type of treatment
Exhibit 21: Drug therapy – Market size and forecast 2017-2022 ($ mn)
Exhibit 22: JAKAVI/JAKAFI sales from 2015-2017
Exhibit 23: Drug therapy – Year-over-year growth 2018-2022 (%)
Exhibit 24:  Blood transfusion – Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Blood transfusion – Year-over-year growth 2018-2022 (%)
Exhibit 26: HSCT – Market size and forecast 2017-2022 ($ mn)
Exhibit 27: HSCT – Year-over-year growth 2018-2022 (%)
Exhibit 28: Androgen therapy – Market size and forecast 2017-2022 ($ mn)
Exhibit 29: Androgen Therapy – Year-over-year growth 2018-2022 (%)
Exhibit 30: Market opportunity by type of treatment
Exhibit 31: Customer landscape
Exhibit 32: Global – Market share by geography 2017-2022 (%)
Exhibit 33: Regional comparison
Exhibit 34: Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 35: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 36: Top 3 countries in Americas
Exhibit 37: EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 38: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 39: Top 3 countries in EMEA
Exhibit 40: APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 41: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 42: Top 3 countries in APAC
Exhibit 43: Market opportunity
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: Bristol-Myers Squibb – Overview
Exhibit 49: Bristol-Myers Squibb – Business segments
Exhibit 50: Bristol-Myers Squibb – Organizational developments
Exhibit 51: Bristol-Myers Squibb – Geographic focus
Exhibit 52: Bristol-Myers Squibb – Key offerings
Exhibit 53: Bristol-Myers Squibb – Key customers
Exhibit 54: CELGENE – Overview
Exhibit 55: CELGENE – Business segments
Exhibit 56: CELGENE – Organizational developments
Exhibit 57: CELGENE – Geographic focus
Exhibit 58: CELGENE – Key offerings
Exhibit 59: CELGENE – Key customers
Exhibit 60: Incyte – Overview
Exhibit 61: Incyte – Business segments
Exhibit 62: Incyte – Organizational developments
Exhibit 63: Incyte – Geographic focus
Exhibit 64: Incyte – Key offerings
Exhibit 65: Incyte – Key customers
Exhibit 66: Novartis – Overview
Exhibit 67: Novartis – Business segments
Exhibit 68: Novartis – Organizational developments
Exhibit 69: Novartis – Geographic focus
Exhibit 70: Novartis – Segment focus
Exhibit 71: Novartis – Key offerings
Exhibit 72: Novartis – Key customers




【掲載企業】

Bristol-Myers Squibb
CELGENE
Incyte
Novartis

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[骨髄線維症治療薬の世界市場2018-2022]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆